First step for new fatty liver drug: safety check in healthy volunteers

This was an early-stage safety study for a potential new medicine called ACT500, which is being developed for a serious liver condition called non-alcoholic steatohepatitis (NASH). The study tested single and multiple doses in 72 healthy Chinese adults to see how safe the drug was and how the body processed it. The main goal was to gather initial safety data and understand how the drug moves through the body before testing it in people who have the disease.